芳香化酶抑制剂引起绝经后乳腺癌患者骨量丢失治疗的国内外进展
Advances in the Treatment of Bone Loss in Postmenopausal Women with Breast Cancer by Aromatase Inhibitors
DOI: 10.12677/TCM.2018.71006, PDF,    科研立项经费支持
作者: 陈婷如, 刘 胜：上海中医药大学附属龙华医院，上海
关键词: 乳腺癌；芳香化酶抑制剂；骨量丢失；中医；Breast Cancer； Aromatase Inhibitors； Bone Loss； Chinese Medicine
摘要: 绝经后妇女因体内雌激素生理性下降而出现骨量丢失，绝经后乳腺癌患者在服用芳香化酶抑制剂后进一步抑制体内雌激素，从而加剧了骨量的丢失而出现了腰背疼痛、膝软无力等症状，严重者引发骨折降低乳腺癌患者生存期。临床常用二膦酸盐、降钙素等提升骨密度，中医选用淫羊藿、骨碎补等单药，六味地黄丸、二仙汤等组方提升骨密度及改善症状。
Abstract: The bone mass is losing in postmenopausal women due to estrogen physiological decline in the body. After the use of aromatase inhibitors, the postmenopausal women with breast cancer fur-ther inhibited the estrogen in the body, which aggravated the loss of bone mass, and presented symptoms such as low back pain, weakness of the knees. A severe bone fracture even reduces the survival of the breast cancer patients. The clinical commonly used bisphosphonates, calcitonin to increase bone density. The Chinese medicine use single herbs such as epimedium, Drynaria, or prescriptions such as Rehmannia six, Erxian decoction to increase bone density and improve symptoms.
文章引用：陈婷如, 刘胜. 芳香化酶抑制剂引起绝经后乳腺癌患者骨量丢失治疗的国内外进展[J]. 中医学, 2018, 7(1): 33-38. https://doi.org/10.12677/TCM.2018.71006

参考文献

[1] 李慧林, 朱汉民, 程群, 陈小平, 朱晓颖, 张雪梅. 绝经妇女绝经后年限及年龄与骨量丢失率关系[J]. 中国骨质疏松杂志, 2007(7): 502-504.
[2] 王宁, 王斌, 王雅杰. 乳腺癌患者发病年龄和临床病理学参数的相关性研究[J]. 临床肿瘤学杂志, 2011(2): 134- 138.
[3] Shapiro, C.L., Manola, J. and Leboff, M. (2001) Ovarian Failure after Adjuvant Chemotherapy Is Associated with Rapid Bone Loss in Women with Early-Stage Breast Cancer. Journal of Clinical Oncology, 14, 3306-3311. [Google Scholar] [CrossRef] 
[4] 孙启慧, 罗东林, 田武国, 郝帅, 赵先英. 他莫昔芬与芳香化酶抑制剂治疗乳腺癌的临床研究进展[J]. 解放军药学学报, 2016, 32(1): 69-73.
[5] Howell, A., Cuzick, J., Baum, M., et al. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years’ Adjuvant Treatment for Breast Cancer. Lancet, 365, 60-62. [Google Scholar] [CrossRef] 
[6] Goss, P.E. (2005) A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. New England Journal of Medicine, 353, 2747-2757. [Google Scholar] [CrossRef] 
[7] Perez, E.A., Josse, R.G., Pritchard, K.I., et al. (2006) Effect of Letrozole versus Placebo on Bone Mineral Density in Women with Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17. Journal of Clinical Oncology, 24, 3629-3635. [Google Scholar] [CrossRef] 
[8] Lønning, P.E., Geisler, J., Krag, L.E., et al. (2005) Effects of Exemestane Administered for 2 Years versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients with Surgically Resected Early Breast Cancer. Journal of the American Society of Clinical Oncology, 23, 5126-5137. [Google Scholar] [CrossRef] 
[9] Porthouse, J., Cockayne, S., King, C., et al. (2005) Randomised Controlled Trial of Calcium and Vitamin D Supplementation for Fracture Prevention in Primary Care. British Medical Journal, 330, 1003. [Google Scholar] [CrossRef] [PubMed]
[10] 林华, 包丽华, 韩祖斌, 孙燕芳, 陈新. 降钙素治疗骨质疏松症骨质量病变的研究[J]. 中华骨科杂志, 2001(9): 6- 8.
[11] 苏娜, 吴逢波, 徐珽. 鲑鱼降钙素致不良反应的文献分析[J]. 华西医学, 2013(2): 253-255.
[12] 抗骨质疏松症药鲑鱼降钙素长期使用具有致癌风险[J]. 药学进展, 2013(4): 188-189.
[13] Brufsky, A.M., Harker, W.G., Beck, J.T., et al. (2012) Final 5-Year Results of Z-FAST Trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole. Cancer, 118, 1192-1201. [Google Scholar] [CrossRef] [PubMed]
[14] 张啟维, 王英民, 薛庆云, 张华俦. 唑来膦酸治疗绝经后骨质疏松早期药物不良反应分析[J]. 中国新药杂志, 2011(8): 757-760.
[15] Rosen, C.J. (1955) Post-Menopausal Osteoporosis. New England Journal of Medicine, 2, 120-121.
[16] 丁瑜莉, 王海霞, 俞腾飞. 他莫昔芬临床应用研究进展[J]. 国际药学研究杂志, 2016(2): 275-279.
[17] 徐春生, 叶仁青. 氟化物在骨质疏松症治疗中的应用[J]. 国外医学: 内分泌学分册, 1998(2): 24-27.
[18] 许英, 王小云. 中草药及药用植物治疗绝经后骨质疏松症——从基础研究到临床评价[J]. 辽宁中医杂志, 2009 (10): 1647-1651.
[19] 李宁. 二仙汤加味防治芳香化酶抑制剂所致乳腺癌患者骨丢失的临床观察[D]: [硕士学位论文]. 北京: 北京中医药大学, 2009: 1-33.
[20] 马翠翠. 六味地黄丸预防乳腺癌患者服用芳香化酶抑制剂所致骨量丢失的临床研究[D]: [硕士学位论文]. 福州: 福建中医学院, 2009: 1-30.
[21] 时百玲. 补肾法对乳腺癌芳香化酶抑制剂所致骨丢失的影响[D]: [硕士学位论文]. 广州: 广州中医药大学, 2010: 1-45.
[22] 吴文, 李东风, 智喜梅, 韩梅清. 仙灵骨葆对绝经后妇女骨质疏松的防治作用[J]. 广州中医药大学学报, 2005(3): 191-193.
[23] Zhang, G., Qin, L. and Shi, Y. (2007) Epimedium-Derived Phytoestrogen Flavonoids Exert Beneficial Effect on Preventing Bone Loss in Late Postmenopausal Women: A 24-Month Randomized, Double-Blind and Placebo-Controlled Trial. Journal of Bone & Mineral Research, 22, 1072-1079. [Google Scholar] [CrossRef] [PubMed]
[24] Zhu, H.M., Qin, L., Garnero, P., et al. (2010) The First Multicenter and Randomized Clinical Trial of Herbal Fufang for Treatment of Postmenopausal Osteoporosis. Osteoporosis International, 47, 457-458.